Merry Christmas & Bright New Year, page-5

As we move into the new year and start to consider investment opportunities, I thought a comment made to me by another investor might be pertinent. Over the past 3-4 years, in any of the preclinical and clinical announcements, has Rac delivered any bad news? We spoke at length about this, the answer we came to was,

There is in human data over a 2-3 year period, only good news and approval in France, etc, etc.
There is 2 trials in Israel (still awaiting full results from second trial) only good news.
Invitro data, good news. Preclinical findings on the anti-cancer efficacy of bisantrene, which demonstrate its potential in enhancing the cancer-killing activity of the widely used drug doxorubicin across a diverse range of 143 human cancer cell lines.
Invivo data, good news.
Reformulation, better IP protection, easier to administer, good news.
CPACS, good news.

The only issue has been a delay in garnering the data required for BP to really want a piece of Rac, this piece is now in place, I as sure there will be other surprises along the way, there is a lot to like in 2024.